Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Cytotoxic CD8⁺ T cells are required for CD20xCD3 bispecific antibody-mediated tumor control in B-cell non-Hodgkin lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJahan RahmanGSGilles Salles

Discussion

Loading...

Member takes

Overview

Observational analysis shows that CD8+ T cells are critical for tumor control in B-cell lymphomas, suggesting strategies for bispecific antibody therapy.

Key Points

  • Tumor control is significantly associated with the presence of cytotoxic CD8+ T cells, indicating their importance in treatment success.
  • Analysis revealed that lower CD8+ T cell infiltration correlates with disease progression in lymphoma patients, highlighting a key response relationship.
  • In vitro cytotoxicity assays confirmed CD8+ T cells escalate target cell lysis compared to other T cell subsets, demonstrating their functional superiority.
  • This study underscores the need for approaches that enhance CD8+ T cell responses to potentially improve anti-lymphoma treatment outcomes.

Cite This Study

Rahman et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc88https://doi.org/10.1182/blood-2025-556
View Full Paper
Ask AI
Bookmark
Share